These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38613340)

  • 1. Clinical Value of Human Endogenous Retrovirus-H Long Terminal Repeat Associating 2 (HHLA2) in Small Cell Lung Cancer.
    Zhang X; Qin Y; Chen X; Xiong M; Shu S
    Technol Cancer Res Treat; 2024; 23():15330338241240683. PubMed ID: 38613340
    [No Abstract]   [Full Text] [Related]  

  • 2. Human Endogenous Retrovirus-H Long Terminal Repeat- Associating Protein 2 (HHLA2) is a Novel Immune Checkpoint Protein in Lung Cancer which Predicts Survival.
    Farrag MS; Ibrahim EM; El-Hadidy TA; Akl MF; Elsergany AR; Abdelwahab HW
    Asian Pac J Cancer Prev; 2021 Jun; 22(6):1883-1889. PubMed ID: 34181347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma.
    Niu Y; Wang W; Jiang X; Huang Y; Yan S; Jiang Y
    Jpn J Clin Oncol; 2022 Jul; 52(7):759-765. PubMed ID: 35348687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human endogenous retrovirus-H long terminal repeat-associating 2: The next immune checkpoint for antitumour therapy.
    Ying H; Xu J; Zhang X; Liang T; Bai X
    EBioMedicine; 2022 May; 79():103987. PubMed ID: 35439678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 is Upregulated and Independently Predicts Unfavorable Prognosis in Bladder Urothelial Carcinoma.
    Lin G; Ye H; Wang J; Chen S; Chen X; Zhang C
    Nephron; 2019; 141(4):256-264. PubMed ID: 30602154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) expression with gastric cancer prognosis.
    Shimonosono M; Arigami T; Yanagita S; Matsushita D; Uchikado Y; Kijima Y; Kurahara H; Kita Y; Mori S; Sasaki K; Omoto I; Maemura K; Uenosono Y; Ishigami S; Natsugoe S
    Oncotarget; 2018 Apr; 9(31):22069-22078. PubMed ID: 29774123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
    Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
    J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of immune-regulatory molecule B7-H4 in small cell lung cancer.
    Zhang X; Song S; Zhang F; Cai L; Xie W
    Ann Palliat Med; 2020 Jul; 9(4):1953-1957. PubMed ID: 32692215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
    Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
    Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Expression Patterns and Associated Clinical Parameters of Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 and Transmembrane and Immunoglobulin Domain Containing 2 in Oral Squamous Cell Carcinoma.
    Xiao Y; Li H; Yang LL; Mao L; Wu CC; Zhang WF; Sun ZJ
    Dis Markers; 2019; 2019():5421985. PubMed ID: 31089395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer.
    Niu Y; Huang Y; Dong A; Sun Y
    Int J Gen Med; 2022; 15():1509-1516. PubMed ID: 35210824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer.
    Wei L; Tang L; Chang H; Huo S; Li Y
    Hum Cell; 2020 Jan; 33(1):116-122. PubMed ID: 31552567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of HHLA2 expression in solid tumors: A meta-analysis based on the Chinese population.
    Zhang C; Xu J; Ye J; Zhang X
    Medicine (Baltimore); 2021 Jul; 100(30):e26789. PubMed ID: 34397730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HHLA2, a New Immune Checkpoint Member of the B7 Family, Is Widely Expressed in Human Lung Cancer and Associated with EGFR Mutational Status.
    Cheng H; Janakiram M; Borczuk A; Lin J; Qiu W; Liu H; Chinai JM; Halmos B; Perez-Soler R; Zang X
    Clin Cancer Res; 2017 Feb; 23(3):825-832. PubMed ID: 27553831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of HHLA2 and CD8 Immunohistochemical Expression in Colorectal Carcinoma and Their Prognostic Significance.
    Gawesh ZM; Ibrahim EM; ElKalla HMHR; Awad AAH; Mohamed MA
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4309-4319. PubMed ID: 38156868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer.
    Zhang X; Xie W; Wang Z; Song S; Qin Y; Zhang F; Chen F; Cai L
    Ann Transl Med; 2020 May; 8(9):589. PubMed ID: 32566616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of HHLA2, TMIGD2, and GITR in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma.
    Zhang MJ; Wang S; Wu CC; Wu L; Sun ZJ
    J Oral Pathol Med; 2022 Apr; 51(4):379-387. PubMed ID: 35226778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HHLA2 immune-regulatory roles in cancer.
    Mortezaee K
    Biomed Pharmacother; 2023 Jun; 162():114639. PubMed ID: 37011487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological suppression of HHLA2 glycosylation restores anti-tumor immunity in colorectal cancer.
    Zhang D; Xie J; Sun F; Xu R; Liu W; Xu J; Huang X; Zhang G
    Cancer Lett; 2024 May; 589():216819. PubMed ID: 38522775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuron-specific enolase and response to initial therapy are important prognostic factors in patients with small cell lung cancer.
    Zhou M; Wang Z; Yao Y; Zhou H; Liu M; Sun J
    Clin Transl Oncol; 2017 Jul; 19(7):865-873. PubMed ID: 28127669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.